English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

For many patients with hematological malignancies, hematopoietic stem cells transplantation is the only potentially curative treatment option, but only 30% of patients have fully HLA-matched donor. In case of urgent need to transplant, use of alternative haploidentical donor can be the only chance for cure. For a long time, usage of haploidentical SCT was limited due to high rate of severe GVHD and graft failure. Introduction of GVHD prophylaxis with рost-transplant Cyclophosphamide (PT-Cy) allowed overcome this barrier [1, 2]. Unfortunately many patients relapse after transplant. In this case, different treatment strategies can be used for induction of remission [4].

cellular therapy and transplantation

Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-SCT) with Post-Transplant Cyclophosphamide for haematological malignancies: a single centre experience